HRP20211430T1 - Postupci, kompleti i uređaj za ekspanziju populacije stanica - Google Patents
Postupci, kompleti i uređaj za ekspanziju populacije stanica Download PDFInfo
- Publication number
- HRP20211430T1 HRP20211430T1 HRP20211430TT HRP20211430T HRP20211430T1 HR P20211430 T1 HRP20211430 T1 HR P20211430T1 HR P20211430T T HRP20211430T T HR P20211430TT HR P20211430 T HRP20211430 T HR P20211430T HR P20211430 T1 HRP20211430 T1 HR P20211430T1
- Authority
- HR
- Croatia
- Prior art keywords
- streptavidin
- analog
- avidin
- binding
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 18
- 108010090804 Streptavidin Proteins 0.000 claims 25
- 239000003153 chemical reaction reagent Substances 0.000 claims 21
- 108090001008 Avidin Proteins 0.000 claims 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 239000011616 biotin Substances 0.000 claims 9
- 229960002685 biotin Drugs 0.000 claims 9
- 235000020958 biotin Nutrition 0.000 claims 9
- 150000001615 biotins Chemical class 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 230000002441 reversible effect Effects 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102000000584 Calmodulin Human genes 0.000 claims 2
- 108010041952 Calmodulin Proteins 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229910001428 transition metal ion Inorganic materials 0.000 claims 2
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/48—Automatic or computerized control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
- C12N2537/10—Cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Sustainable Development (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Computer Hardware Design (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
Claims (16)
1. Postupak in vitro za ekspanziju populacije stanica, naznačen time, da postupak obuhvaća inkubaciju uzorka koji sadrži populaciju stanica u prisutnosti multimerizacijskog reagensa koji je reverzibilno vezan s prvim agensom i s drugim agensom,
pri čemu se prvi agens veže na receptorsku molekulu na površini stanica u populaciji, i koji je sposoban za davanje primarnog aktivacijskog signala stanicama, i
pri čemu se drugi agens veže na pomoćnu molekulu na površini stanica u populaciji, i koji je sposoban za stimulaciju stanica,
gdje prvi agens (i) sadrži najmanje jedan vezni partner C1 sposoban za reverzibilno vezanje na mjesto vezanja Z1 multimerizacijskog reagensa u svrhu tvorbe reverzibilne veze između veznog partnera C1 i mjesta vezanja Z1, i gdje drugi agens (i) sadrži najmanje jedan vezni partner C2 sposoban za reverzibilno vezanje na mjesto vezanja Z2 multimerizacijskog reagensa u svrhu tvorbe reverzibilne veze između veznog partnera C2 i mjesta vezanja Z2.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da se kod populacije stanica radi o populaciji limfocita.
3. Postupak prema patentnom zahtjevu 2, naznačen time, da se kod populacije limfocita radi o populaciji B stanica, populaciji T stanica, populaciji prirodnih stanica ubojica ili o njihovim mješavinama.
4. Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da prvi agens daje primarni signal stanicama.
5. Postupak prema patentnom zahtjevu 3, naznačen time, da:
populacija stanica sadrži populaciju T stanica i prvi agens sadrži MHC I:peptidni kompleks ili stimulira TCR/CD3 signal povezan s kompleksom u T stanicama i/ili sadrži vezujući reagens koji se veže na CD3.
6. Postupak prema patentnom zahtjevu 3, naznačen time, da:
populacija stanica sadrži populaciju B stanica i receptorska molekula je CD40 ili CD137 i/ili prvi agens sadrži vezujući reagens koji se veže na CD40 ili CD137.
7. Postupak prema patentnom zahtjevu 5, naznačen time, da populacija stanica sadrži populaciju T stanica i pomoćna molekula je CD28 ili CD137 i/ili drugi agens sadrži vezujući reagens koji se veže na CD28 ili CD137 ili je mješavina od dva različita vezujuća reagensa od kojih se oba specifično vežu na CD28 ili CD137.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da se multimerizacijski reagens imobilizira na krutoj podlozi.
9. Postupak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da se multimerizacijski reagens bira iz skupine koja se sastoji od streptavidina, avidina, analoga streptavidina koji se reverzibilno veže na biotin, analoga avidina koji se reverzibilno veže na biotin, reagensa koji sadrži najmanje dvije kelatne skupine K, pri čemu su najmanje dvije kelatne skupine sposobne za vezanje na prijelazni metalni ion, čime se ostatak A osposobljava za vezanje na afinitetnu oznaku oligohistidina, multimernu glutationsku S transferazu, multimerni kalmodulin i biotinilirani nosač proteina.
10. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da se multimerizacijski reagens nalazi u topivom obliku.
11. Postupak prema patentnom zahtjevu 10, naznačen time, da multimerizacijski reagens sadrži oligomer ili polimer streptavidina, oligomer ili polimer avidina, oligomer ili polimer analoga streptavidina koji se reverzibilno veže na biotin, oligomer ili polimer analoga avidina koji se reverzibilno veže na biotin, reagens koji sadrži najmanje dvije kelatne skupine K, pri čemu su najmanje dvije kelatne skupine sposobne za vezanje na prijelazni metalni ion, čime se ostatak A osposobljava za vezanje na afinitetnu oznaku oligohistidina, multimernu glutationsku S transferazu, multimerni kalmodulin i biotinilirani nosač proteina.
12. Postupak prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da:
(a) spomenuti vezni partner C1 i/ili spomenuti vezni partner C2 sadrže biotin i spomenuti multimerizacijski reagens sadrži analog streptavidina ili analog avidina koji sa reverzibilno veže na biotin;
(b) spomenuti vezni partner C1 i/ili spomenuti vezni partner C2 sadrže analog biotina koji se reverzibilno veže na streptavidin ili avidin i spomenuti multimerizacijski reagens sadrži streptavidin, ili avidin, ili analog streptavidina, ili analog avidina koji se reverzibilno veže na spomenuti analog biotina; ili
(c) spomenuti vezni partner C1 i/ili spomenuti vezni partner C2 sadrže peptid koji veže streptavidin ili avidin i spomenuti multimerizacijski reagens sadrži streptavidin, ili avidin, ili analog streptavidina, ili analog avidina koji se reverzibilno veže na spomenuti peptid koji veže streptavidin ili avidin.
13. Postupak prema patentnom zahtjevu 12, naznačen time, da spomenuti vezni partner C1 i/ili spomenuti vezni partner C2 sadrže peptid Trp-Ser-His-Pro-Gln-Phe-Glu-Lys koji veže streptavidin i spomenuti multimerizacijski reagens sadrži analog streptavidina koji sadrži aminokiselinski slijed Val44-Thr45-Ala46-Arg47 na pozicijama 44 do 47 slijeda divljeg tipa streptavidina ili analog streptavidina koji sadrži aminokiselinski slijed Ile44-Gly45-Ala46-Arg47 na pozicijama 44 do 47 slijeda divljeg tipa streptavidina.
14. Postupak prema bilo kojem od patentnih zahtjeva 2 do 13, naznačen time, da su vezni partneri C1 i C2 isti ili različiti.
15. Postupak prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da nadalje obuhvaća prekidanje vezanja između navedenog veznog partnera C1 od prvog agensa i/ili navedenog veznog partnera C2 od drugog agensa i navedenih mjesta vezanja Z1 i/ili Z2 spomenutog multimerizacijskog reagensa, dok opcionalno pritom navedeno prekidanje uzrokuje završetak stimulacije stanica.
16. Postupak prema patentnom zahtjevu 15, naznačen time, da se reverzibilna veza prekida putem stavljanja stanica u doticaj s biotinom ili analogom biotina, kada
(a) navedeni vezni partneri C1 i C2 međusobno neovisno sadrže biotin i navedeni multimerizacijski reagens sadrži analog streptavidina ili analog avidina koji se reverzibilno veže na biotin;
(d) navedeni vezni partneri C1 i C2 međusobno neovisno sadrže analog biotina koji se reverzibilno veže na streptavidin ili avidin i navedeni multimerizacijski reagens sadrži streptavidin, ili avidin, ili analog streptavidina, ili analog avidina koji se reverzibilno veže na spomenuti analog biotina; ili
(e) navedeni vezni partneri C1 i C2 međusobno neovisno sadrže peptid koji veže streptavidin ili avidin i navedeni multimerizacijski reagens sadrži streptavidin, ili avidin, ili analog streptavidina, ili analog avidina koji se reverzibilno veže na spomenuti peptid koji veže streptavidin ili avidin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461980506P | 2014-04-16 | 2014-04-16 | |
EP15720620.2A EP3132247B1 (en) | 2014-04-16 | 2015-04-16 | Methods, kits and apparatus for expanding a population of cells |
PCT/EP2015/058339 WO2015158868A2 (en) | 2014-04-16 | 2015-04-16 | Methods, kits and apparatus for expanding a population of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211430T1 true HRP20211430T1 (hr) | 2021-12-10 |
Family
ID=53052805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211430TT HRP20211430T1 (hr) | 2014-04-16 | 2021-09-13 | Postupci, kompleti i uređaj za ekspanziju populacije stanica |
Country Status (26)
Country | Link |
---|---|
US (2) | US11274278B2 (hr) |
EP (2) | EP3988920A1 (hr) |
JP (3) | JP6696969B2 (hr) |
KR (2) | KR102459384B1 (hr) |
CN (3) | CN116656605A (hr) |
AU (2) | AU2015248786B2 (hr) |
BR (1) | BR112016024072B1 (hr) |
CA (2) | CA2945889C (hr) |
CY (1) | CY1124717T1 (hr) |
DK (1) | DK3132247T3 (hr) |
ES (1) | ES2892927T3 (hr) |
HR (1) | HRP20211430T1 (hr) |
HU (1) | HUE056852T2 (hr) |
IL (3) | IL280738B (hr) |
LT (1) | LT3132247T (hr) |
MX (2) | MX2016013493A (hr) |
MY (1) | MY184699A (hr) |
PH (2) | PH12016502017A1 (hr) |
PL (1) | PL3132247T3 (hr) |
PT (1) | PT3132247T (hr) |
RS (1) | RS62471B1 (hr) |
RU (2) | RU2020133435A (hr) |
SA (1) | SA516380090B1 (hr) |
SG (2) | SG10201808491UA (hr) |
SI (1) | SI3132247T1 (hr) |
WO (1) | WO2015158868A2 (hr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106940268B (zh) | 2012-02-23 | 2021-09-21 | 朱诺治疗有限公司 | 细胞和其它复杂生物材料的色谱分离 |
CN116656605A (zh) | 2014-04-16 | 2023-08-29 | 朱诺治疗有限公司 | 用于扩增细胞群的方法、试剂盒及装置 |
KR20220136455A (ko) | 2014-04-23 | 2022-10-07 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법 |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
RU2021134624A (ru) * | 2015-10-22 | 2022-03-15 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
MA45488A (fr) * | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
EP3192810A1 (en) | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
CN107129988A (zh) * | 2016-02-29 | 2017-09-05 | 广西医科大学 | 一种特异性结合cd3的核酸适配体及其筛选方法和应用 |
BR112018073909A2 (pt) * | 2016-06-02 | 2019-02-26 | Klotho Therapeutics, Inc. | proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas |
JP7062640B2 (ja) | 2016-07-29 | 2022-05-06 | ジュノー セラピューティクス インコーポレイテッド | 抗cd19抗体に対する抗イディオタイプ抗体 |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
CN110249046A (zh) * | 2016-12-05 | 2019-09-17 | 朱诺治疗学股份有限公司 | 用于过继细胞疗法的工程化细胞的产生 |
US11624046B2 (en) * | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
CN117247899A (zh) * | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
CA3060526A1 (en) * | 2017-04-27 | 2018-11-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
MA51154A (fr) * | 2017-12-15 | 2020-10-21 | Aleta Biotherapeutics Inc | Variants de cd19 |
CN107904278B (zh) * | 2017-12-25 | 2021-07-20 | 北昊干细胞与再生医学研究院有限公司 | 检测药物对细胞增殖影响的方法 |
US11149244B2 (en) * | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
EP3790958A1 (en) * | 2018-05-08 | 2021-03-17 | Life Technologies Corporation | Compositions and methods for culturing and expanding cells |
WO2019226529A1 (en) * | 2018-05-21 | 2019-11-28 | Bioprocessia Technologies Llc | Multivalent protein complexes |
BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
BR112021004686A2 (pt) | 2018-09-11 | 2021-06-08 | Eberhard Karls Universität Tübingen | proteínas de ligação de antígeno anti-flt3 melhoradas |
EP3623383A1 (en) | 2018-09-11 | 2020-03-18 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved bispecific flt3xcd3 antigen binding proteins |
EP3856888A4 (en) * | 2018-09-24 | 2022-10-12 | Southwest Research Institute | THREE-DIMENSIONAL BIOREACTORS |
BR112021008133A2 (pt) | 2018-10-31 | 2021-10-05 | Juno Therapeutics Gmbh | Métodos para seleção e estimulação de células e aparelhos para os mesmos |
KR20200132147A (ko) * | 2019-05-15 | 2020-11-25 | 의료법인 성광의료재단 | 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법 |
EP3978925A4 (en) * | 2019-05-24 | 2023-06-28 | Sol Bio Corporation | Affinity separation system and method using switch-like adhesion reaction |
AU2020287882A1 (en) * | 2019-06-07 | 2022-01-20 | Juno Therapeutics, Inc. | Automated T cell culture |
JP2023500318A (ja) | 2019-10-30 | 2023-01-05 | ジュノ セラピューティクス ゲーエムベーハー | 細胞選択および/または細胞刺激デバイスならびに使用方法 |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
EP4069742A1 (en) | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
CN115916817A (zh) | 2019-12-06 | 2023-04-04 | 朱诺治疗学股份有限公司 | 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法 |
JP2023509802A (ja) | 2020-01-31 | 2023-03-09 | セル.コペディア ゲーエムベーハー | 生物学的実体を単離する方法 |
JP2023519098A (ja) | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Cd19指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用 |
KR20220152227A (ko) | 2020-02-12 | 2022-11-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Bcma-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도 |
EP4192868A1 (en) | 2020-08-05 | 2023-06-14 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
CN116802203A (zh) | 2020-11-04 | 2023-09-22 | 朱诺治疗学股份有限公司 | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
EP4373920A1 (en) | 2021-07-19 | 2024-05-29 | Repairon Immuno GmbH | Method of producing a population of immune cells from pluripotent stem cells |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
WO1986002077A1 (en) | 1984-10-02 | 1986-04-10 | Meade Harry M | Production of streptavidin-like polypeptides |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
DK0700430T3 (da) | 1993-06-04 | 2005-08-15 | Us Navy | Fremgangsmåder til selektivt af stimulere proliferation af T-celler |
AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
JPH11501008A (ja) | 1995-02-09 | 1999-01-26 | ユニバーシティ オブ ワシントン | 改変−アフィニティーストレプトアビジン |
WO1997011183A1 (en) | 1995-04-11 | 1997-03-27 | Trustees Of Boston University | Streptavidin mutants |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
CA2283716A1 (en) | 1997-03-14 | 1998-09-17 | Gabriel O. Reznik | Multiflavor streptavidin |
US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
US6664042B1 (en) | 1999-01-26 | 2003-12-16 | Cornell Research Foundation, Inc. | Determining viral load in double negative T cells |
NZ551331A (en) * | 1999-02-03 | 2008-08-29 | Amgen Inc | Methods using polypeptides involved in immune response |
AU759719B2 (en) | 1999-02-04 | 2003-04-17 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
ATE370159T1 (de) | 2002-03-01 | 2007-09-15 | Volker A Erdmann | Streptavidin-bindungspeptid |
US7754155B2 (en) | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
US20050271653A1 (en) | 2002-04-23 | 2005-12-08 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
FR2841905B1 (fr) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications |
WO2004029221A2 (en) | 2002-09-27 | 2004-04-08 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
WO2004096975A2 (en) | 2003-05-02 | 2004-11-11 | Insception Bioscience, Inc. | Apparatus and methods for amplification of blood stem cell numbers |
CA2525519A1 (en) * | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
EP1690090A1 (en) | 2003-11-20 | 2006-08-16 | Biosensor Applications Sweden AB (Publ) | Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture |
SE0400181D0 (sv) | 2004-01-29 | 2004-01-29 | Gyros Ab | Segmented porous and preloaded microscale devices |
DE602005013957D1 (de) | 2004-06-03 | 2009-05-28 | Meso Scale Technologies Llc | Verfahren zur durchführung von vollbluttests |
JP5255841B2 (ja) | 2004-10-15 | 2013-08-07 | ジェネンコー・インターナショナル・インク | 競合示差スクリーニング |
WO2006058226A2 (en) * | 2004-11-24 | 2006-06-01 | The Trustees Of Boston University | Modified dimeric streptavidins and uses thereof |
US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
US7704708B2 (en) * | 2006-02-13 | 2010-04-27 | Uti Limited Partnership | Monomeric streptavidin muteins |
US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
US20090208471A1 (en) | 2006-04-07 | 2009-08-20 | Yun Theodore J | Isolation and Use of Human Regulatory T Cells |
US20080085532A1 (en) | 2006-09-18 | 2008-04-10 | Jorn Gorlach | Method for determining the immune status of a subject |
EP2687540A1 (en) | 2006-10-17 | 2014-01-22 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
WO2008053973A1 (en) | 2006-11-02 | 2008-05-08 | Kyowa Medex Co., Ltd. | Method of immunoassay of component to be measured |
AU2007353319A1 (en) | 2006-11-15 | 2008-11-20 | Invitrogen Dynal As | Methods for reversibly binding a biotin compound to a support |
US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
WO2008118476A2 (en) * | 2007-03-26 | 2008-10-02 | Codon Devices, Inc. | Cell surface display, screening and production of proteins of interest |
EP3023436A1 (en) | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
AU2008290537B2 (en) | 2007-08-20 | 2014-04-03 | Nextera As | pVII phage display |
ES2640216T3 (es) | 2007-12-07 | 2017-11-02 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
EP3358354B1 (en) | 2008-01-18 | 2020-07-15 | President and Fellows of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
ES2890729T3 (es) | 2008-01-29 | 2022-01-21 | Hutchinson Fred Cancer Res | Identificación de células T CD8+ que son CD161hi y/o IL-18Rahi y que tienen una capacidad de evacuación rápida de fármacos |
CN101446576B (zh) | 2008-12-29 | 2011-06-22 | 江苏省苏微微生物研究有限公司 | 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法 |
WO2010080032A2 (en) | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
WO2011053971A2 (en) * | 2009-11-02 | 2011-05-05 | Fina Biosolutions, Llc | Method for enhancing the sensitivity of antibody based assays |
US20120321665A1 (en) * | 2009-12-14 | 2012-12-20 | Benaroya Research Institute At Virginia Mason | Compositions and methods for treating airway inflammatory diseases |
EP2363501A1 (en) | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
EP3376225A1 (en) | 2010-08-06 | 2018-09-19 | Ludwig-Maximilians-Universität München | Identification of t cell target antigens |
WO2012058627A2 (en) | 2010-10-29 | 2012-05-03 | Miqin Zhang | Pre-targeted nanoparticle system and method for labeling biological particles |
ES2841983T3 (es) | 2011-03-23 | 2021-07-12 | Hutchinson Fred Cancer Res | Método y composiciones para inmunoterapia celular |
CN103797028B (zh) | 2011-07-18 | 2017-08-25 | Iba 股份有限公司 | 使靶细胞可逆染色的方法 |
US9353161B2 (en) | 2011-09-13 | 2016-05-31 | Uti Limited Partnership | Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins |
CN106940268B (zh) | 2012-02-23 | 2021-09-21 | 朱诺治疗有限公司 | 细胞和其它复杂生物材料的色谱分离 |
UA114108C2 (uk) * | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
CA2878862C (en) | 2012-07-13 | 2023-01-10 | The Trustees Of The University Of Pennsylvania | Methods of assessing the suitability of transduced t cells for administration |
WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
WO2014076277A1 (en) | 2012-11-16 | 2014-05-22 | Iba Gmbh | Streptavidin muteins and methods of using them |
CN103305464B (zh) | 2013-06-05 | 2015-04-15 | 南昌大学 | 直接分离cd4+和cd8+淋巴细胞的方法 |
US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
SG10201804439PA (en) | 2013-12-20 | 2018-06-28 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
KR20240042250A (ko) | 2014-04-07 | 2024-04-01 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
CN116656605A (zh) * | 2014-04-16 | 2023-08-29 | 朱诺治疗有限公司 | 用于扩增细胞群的方法、试剂盒及装置 |
KR20220136455A (ko) | 2014-04-23 | 2022-10-07 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법 |
US10131876B2 (en) | 2014-04-24 | 2018-11-20 | Miltenyi Biotec Gmbh | Method for automated generation of genetically modified T cells |
RU2741899C2 (ru) | 2014-04-25 | 2021-01-29 | Блубёрд Био, Инк. | Улучшенные способы производства средств адоптивной клеточной терапии |
CN106662584B (zh) * | 2014-04-30 | 2020-05-05 | Iba股份有限公司 | 分离靶细胞的方法 |
MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
RU2021134624A (ru) | 2015-10-22 | 2022-03-15 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
JP7184645B2 (ja) | 2015-12-03 | 2022-12-06 | ジュノー セラピューティクス インコーポレイテッド | 修飾キメラ受容体ならびに関連する組成物および方法 |
CA3060526A1 (en) | 2017-04-27 | 2018-11-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
BR112021008133A2 (pt) | 2018-10-31 | 2021-10-05 | Juno Therapeutics Gmbh | Métodos para seleção e estimulação de células e aparelhos para os mesmos |
-
2015
- 2015-04-16 CN CN202310417528.8A patent/CN116656605A/zh active Pending
- 2015-04-16 PL PL15720620T patent/PL3132247T3/pl unknown
- 2015-04-16 BR BR112016024072-3A patent/BR112016024072B1/pt active IP Right Grant
- 2015-04-16 RU RU2020133435A patent/RU2020133435A/ru unknown
- 2015-04-16 LT LTEPPCT/EP2015/058339T patent/LT3132247T/lt unknown
- 2015-04-16 KR KR1020167031915A patent/KR102459384B1/ko active IP Right Grant
- 2015-04-16 KR KR1020227036837A patent/KR20220150988A/ko not_active Application Discontinuation
- 2015-04-16 DK DK15720620.2T patent/DK3132247T3/da active
- 2015-04-16 US US15/304,045 patent/US11274278B2/en active Active
- 2015-04-16 EP EP21191440.3A patent/EP3988920A1/en active Pending
- 2015-04-16 CA CA2945889A patent/CA2945889C/en active Active
- 2015-04-16 CN CN201580032543.4A patent/CN106414724A/zh active Pending
- 2015-04-16 SG SG10201808491UA patent/SG10201808491UA/en unknown
- 2015-04-16 MY MYPI2016703777A patent/MY184699A/en unknown
- 2015-04-16 IL IL280738A patent/IL280738B/en unknown
- 2015-04-16 PT PT157206202T patent/PT3132247T/pt unknown
- 2015-04-16 SI SI201531727T patent/SI3132247T1/sl unknown
- 2015-04-16 MX MX2016013493A patent/MX2016013493A/es unknown
- 2015-04-16 CA CA3176848A patent/CA3176848A1/en active Pending
- 2015-04-16 IL IL293587A patent/IL293587A/en unknown
- 2015-04-16 RU RU2016144724A patent/RU2735640C9/ru active
- 2015-04-16 JP JP2017505717A patent/JP6696969B2/ja active Active
- 2015-04-16 ES ES15720620T patent/ES2892927T3/es active Active
- 2015-04-16 AU AU2015248786A patent/AU2015248786B2/en active Active
- 2015-04-16 RS RS20211143A patent/RS62471B1/sr unknown
- 2015-04-16 SG SG11201608557UA patent/SG11201608557UA/en unknown
- 2015-04-16 EP EP15720620.2A patent/EP3132247B1/en active Active
- 2015-04-16 HU HUE15720620A patent/HUE056852T2/hu unknown
- 2015-04-16 WO PCT/EP2015/058339 patent/WO2015158868A2/en active Application Filing
- 2015-04-16 CN CN202010423347.2A patent/CN111961647A/zh active Pending
-
2016
- 2016-10-11 PH PH12016502017A patent/PH12016502017A1/en unknown
- 2016-10-13 IL IL248360A patent/IL248360B/en active IP Right Grant
- 2016-10-13 MX MX2020014089A patent/MX2020014089A/es unknown
- 2016-10-16 SA SA516380090A patent/SA516380090B1/ar unknown
-
2020
- 2020-04-23 JP JP2020076705A patent/JP2020124210A/ja active Pending
- 2020-07-01 PH PH12020551028A patent/PH12020551028A1/en unknown
-
2021
- 2021-09-13 HR HRP20211430TT patent/HRP20211430T1/hr unknown
- 2021-11-02 CY CY20211100943T patent/CY1124717T1/el unknown
-
2022
- 2022-01-27 AU AU2022200527A patent/AU2022200527A1/en active Pending
- 2022-03-11 US US17/693,292 patent/US20220195388A1/en active Pending
-
2023
- 2023-02-20 JP JP2023024443A patent/JP2023062124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211430T1 (hr) | Postupci, kompleti i uređaj za ekspanziju populacije stanica | |
JP2017513524A5 (hr) | ||
NZ741859A (en) | Methods for culturing cells and kits and apparatus for same | |
MX2022012147A (es) | Metodos para cultivar celulas y kits y aparatos para ello. | |
Fang et al. | Dbf4 recruitment by forkhead transcription factors defines an upstream rate-limiting step in determining origin firing timing | |
AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
MX2022010686A (es) | Metodos, kits, agentes y aparatos para transduccion. | |
US9631226B2 (en) | Agents providing controls and standards for immunoprecipitation assays | |
BRPI0812878C1 (pt) | anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor | |
JP2004525354A5 (hr) | ||
WO2008140573A3 (en) | Methods for reversibly binding a biotin compound to a support | |
Chisty et al. | Monomeric PcrA helicase processively unwinds plasmid lengths of DNA in the presence of the initiator protein RepD | |
EP3794120A4 (en) | METHODS AND REAGENTS FOR RESOLVING MIXTURES OF NUCLEIC ACIDS AND MIXED CELL POPULATIONS AND RELATED APPLICATIONS | |
Chodavarapu et al. | Two forms of ribosomal protein L2 of Escherichia coli that inhibit DnaA in DNA replication | |
Datta et al. | Physical and functional interaction between nucleoid‐associated proteins HU and Lsr2 of Mycobacterium tuberculosis: altered DNA binding and gene regulation | |
Pullara et al. | A general path for large-scale solubilization of cellular proteins: from membrane receptors to multiprotein complexes | |
BR112018008113A2 (pt) | veículo de cromatografia de afinidade e método para purificar a substância biológica | |
WO2016048994A3 (en) | Systems and methods of cell-free protein synthesis in droplets and other compartments | |
WO2005010484A3 (en) | Methods for identifying cell surface receptor protein modulators | |
Husain et al. | Native Co-immunoprecipitation assay to identify interacting partners of chromatin-associated proteins in mammalian cells | |
MX2022010733A (es) | Metodos para mejorar la calidad del semen. | |
WO2020131182A3 (en) | Compounds, compositions, and methods for improving assays | |
Cencic et al. | A cautionary note on the use of cap analogue affinity resins | |
JP2019532255A5 (hr) | ||
Panigrahi et al. | A SWI/SNF-like factor from chicken liver that disrupts nucleosomes and transfers histone octamers in cis and trans |